Clinical trials: Peritoneal Dialysis
Anaemia
Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
GSK1278863 is an orally-active, novel small molecule agent which inhibits hypoxia-inducible factor (HIF) prolyl -4- hydroxylases (PHDs) and is in development for the treatment of anaemia associated with chronic kidney disease…
- Trial name
- NCT02243306
- Testing
- GSK1278863
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hypoplastic Left Heart Syndrome
Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure
Babies born with hypoplastic left heart syndrome (HLHS) have three separate, complex heart surgeries before they turn three years of age. The first surgery typically happens in the first two weeks of life.
- Trial name
- NCT01215240
- Testing
- Peritoneal dialysis
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Alberta
End Stage Renal Disease
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD).
- Trial name
- NCT02617784
- Testing
- Oseltamivir
- Where
- New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Iron Deficiency Anemia
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
- Trial name
- NCT00223977
- Testing
- Sodium Ferric Gluconate Complex, Oral Iron
- Where
- 43 sites in United States, Bulgaria and 6 more
- Volunteers
- 146 people
- Sponsor
- Watson Pharmaceuticals
Peritoneal Dialysis Associated Peritonitis
Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
Intra-peritoneal administration of antibiotics covering both gram-positive and gram-negative organisms was recommended as first-line regimen for the management of peritoneal dialysis related peritonitis.
- Trial name
- PD (NCT02787057)
- Testing
- vancomycin, moxifloxacin, ceftazidime
- Volunteers
- 80 people
- Sponsor
- Peking University First Hospital
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with stage 5 CKD receiving Peritoneal…
- Trial name
- NCT04064827
- Testing
- Paricalcitol
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 2 people
- Sponsor
- AbbVie
Infectious Peritonitis
Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
This study will evaluate the pharmacokinetic properties of dalbavancin when administered as an intravenous infusion and instilled into the peritoneal space in patients who are undergoing peritoneal dialysis.
- Trial name
- NCT02940730
- Testing
- Dalbavancin via Intravenous Administration, Dalbavancin via Intraperitoneal Administration
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Chronic Kidney Disease
Empowering Patients on Choices for Renal Replacement Therapy (Aim 2)
Empowering Patients On Choices for Renal Replacement Therapy (EPOCH-RRT) study seeks to identify factors that matter the most to patients with kidney disease and study how they are impacted by different types of dialysis.
- Trial name
- EPOCH-RRT (NCT02440659)
- Where
- United States
- Volunteers
- 2,946 people, healthy volunteers welcome
- Sponsor
- Arbor Research Collaborative for Health
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in PD US Trial
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02468414
- Testing
- MDGN201 TARGTEPO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Anemia
Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis
This is a open-label, prospective study comparing intravenous (IV) iron supplementation to standard care in anemic patents undergoing peritoneal dialysis.
- Trial name
- NCT00236938
- Testing
- Venofer and stable erythropoietin (EPO) regimen, stable erythropoietin (EPO) regimen
- Volunteers
- 121 people
- Sponsor
- American Regent, Inc.
End-Stage Renal Disease
L-Carnitine in Peritoneal Dialysis
The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy.
- Trial name
- NCT00922701
- Testing
- L-carnitine
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- Iperboreal Pharma Srl
Anemia
Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.
The purpose of this study is to determine the efficacy and safety of peginesatide injection for maintenance treatment of anemia in participants on peritoneal dialysis.
- Trial name
- NCT00752791
- Testing
- Peginesatide
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
This study adopts a multicenter, open, prospective, and self controlled study design, in which each participant serves as their own control before and after receiving amino acid peritoneal dialysis solution treatment to compare…
- Trial name
- NCT06358820
- Testing
- Amino acid peritoneal dialysis solution
- Where
- China
- Volunteers
- 149 people
- Sponsor
- The People's Hospital of Gaozhou